Pharmafile Logo
Pharmafocus logo
Advanced Search

Shares

Showing 15 posts of 23 posts found.

business-laptop-computer-money

Acasti’s shares plunge as new drug does not meet primary endpoint

January 14, 2020
Manufacturing and Production Acasti, Acasti Pharma, CaPre, Primary Endpoint, Shares

Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …

News
novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

News
novo_flag

Novo Holdings invests £53.5 million into Oxford Biomedica

May 30, 2019
Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …

News
5204602349_c87b204860_z

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019
Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …

News
gilead-sciences

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …

News
johnson_and_johnson_jj

J&J announces $5bn share repurchase

December 18, 2018
Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal

New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …

News
samsung

Samsung Biologics shares fall by 20% after Korean investigation

November 13, 2018
Manufacturing and Production Shares, accounting, pharma, smasung biologics, stockmarket

Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South …

News
stock-exchange-911613_1920

Pharma stocks soar after US midterm elections

November 8, 2018
Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market

Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …

News

Shares in Molecular Templates surge after the announcement of Takeda collaboration

September 20, 2018
Business Services, Research and Development Molecular Templates, Shares, Takeda, markets, stocks

Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with …

News

Realm Therapeutics shares halved after failure of Phase 2 study

August 15, 2018
Research and Development London, Shares, atopic dermatitis, phase 2, stock market

Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …

News
800px-t_lymphocyte_16760076824

Regeneron Pharma and Bluebird bio announce immune cell collaboration

August 6, 2018
Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells

Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …

News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …

Feature
stocks1

Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …

Feature
stocks2

Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016
Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024